Last reviewed · How we verify
Methadol (DIMEPHEPTANOL)
Methadol (generic name: DIMEPHEPTANOL) is a drug. It is currently in Phase 2 development.
Methadol is thought to work by interacting with a specific molecular target, although its exact mechanism of action is currently unknown.
Methadol, also known as Dimepheptanol, is a small molecule compound with unknown target and drug class. Its commercial status and approved indications are unclear. As a research compound, it may have potential therapeutic applications, but further investigation is needed to determine its efficacy and safety. Key safety considerations are unknown, and its half-life, bioavailability, and generic manufacturers are also unclear. Further research is required to fully understand Methadol's properties and potential uses.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DIMEPHEPTANOL |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have locks on them, and Methadol is a key that fits into one of those locks. When it binds to the lock, it can either turn the lock to open the cell or block other keys from entering. However, the specific lock that Methadol fits into and how it affects the cell's behavior are still unknown.
Approved indications
Common side effects
Key clinical trials
- LAAM-HAART PET Imaging (EARLY_PHASE1)
- Feasibility Study of Take-Home LAAM Medication - 3 (PHASE4)
- The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1 (PHASE2)
- Evaluation of L-alpha-acetylmethadol (LAAM) in Methadone Patients - 5 (PHASE2)
- Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methadol CI brief — competitive landscape report
- Methadol updates RSS · CI watch RSS
Frequently asked questions about Methadol
What is Methadol?
How does Methadol work?
What is the generic name of Methadol?
What development phase is Methadol in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing